Major depression and its treatment: MicroRNAs as peripheral biomarkers of diagnosis and treatment response

Current Opinion in Psychiatry

Volumn 31, Issue 1, 2018, Pages 7-16

  Lopez, Juan Pablo ^a,b   Kos, Aron ^b   Turecki, Gustavo ^a  

^a MCGILL UNIVERSITY   (Canada)

^b MAX PLANCK INSTITUTE OF PSYCHIATRY   (Germany)

Author keywords

Antidepressant treatment; Biomarker; Major depressive disorder; microRNA

Indexed keywords

ANTIDEPRESSANT AGENT; MICRORNA; BIOLOGICAL MARKER;

GENE EXPRESSION; HUMAN; MAJOR DEPRESSION; NONHUMAN; REGULATORY MECHANISM; REVIEW; TREATMENT RESPONSE; BLOOD; GENETICS; METABOLISM; TREATMENT OUTCOME;

ANTIDEPRESSIVE AGENTS; BIOMARKERS; DEPRESSIVE DISORDER, MAJOR; HUMANS; MICRORNAS; TREATMENT OUTCOME;

EID: 85036609658     PISSN: 09517367     EISSN: 14736578     Source Type: Journal    
DOI: 10.1097/YCO.0000000000000379     Document Type: Review

References (67)

1. Otte C, Gold SM, Penninx BW, et al. Major depressive disorder. Nat Rev Dis Primers 2016; 2:16065.
2. Lam RW, Milev R, Rotzinger S, et al. Discovering biomarkers for antidepressant response: protocol from the Canadian biomarker integration network in depression (CAN-BIND) and clinical characteristics of the first patient cohort. BMC Psychiatry 2016; 16:105.
3. Kennedy SH, Downar J, Evans KR, et al. The Canadian Biomarker Integration Network in Depression (CAN-BIND): advances in response prediction. Curr Pharm Des 2012; 18:5976-5989.
4. Issler O, Chen A. Determining the role of microRNAs in psychiatric disorders. Nat Rev Neurosci 2015; 16:201-212.
5. Kocerha J, Dwivedi Y, Brennand KJ. Noncoding RNAs and neurobehavioral mechanisms in psychiatric disease. Mol Psychiatry 2015; 20:677-684.
6. Belzeaux R, Lin R, Turecki G. Potential use of microRNA for monitoring therapeutic response to antidepressants. CNS Drugs 2017; 31:253-262.
7. Qureshi IA, Mehler MF. Emerging roles of noncoding RNAs in brain evolution, development, plasticity and disease. Nat Rev Neurosci 2012; 13:528-541.
8. Yates LA, Norbury CJ, Gilbert RJ. The long and short of microRNA. Cell 2013; 153:516-519.
9. Esteller M. Noncoding RNAs in human disease. Nat Rev Genet 2011; 12:861-874.
10. St Laurent G, Wahlestedt C, Kapranov P. The landscape of long noncoding RNA classification. Trends Genet 2015; 31:239-251.
11. Ha M, Kim VN. Regulation of microRNA biogenesis. Nat Rev Mol Cell Biol 2014; 15:509-524.
12. Hu W, Coller J. What comes first: translational repression or mRNA degradation? The deepening mystery of microRNA function. Cell Res 2012; 22:1322-1324.
13. He L, Hannon GJ. MicroRNAs: small RNAs with a big role in gene regulation. Nat Rev Genet 2004; 5:522-531.
14. Ziats MN, Rennert OM. Identification of differentially expressed microRNAs across the developing human brain. Mol Psychiatry 2013; 19:848-852.
15. Hunsberger JG, Austin DR, Chen G, Manji HK. MicroRNAs in mental health: from biological underpinnings to potential therapies. Neuromolecular Med 2009; 11:173-182.
16. Xu B, Karayiorgou M, Gogos JA. MicroRNAs in psychiatric and neurodevelopmental disorders. Brain Res 2010; 1338:78-88.
17. Miller BH, Wahlestedt C. MicroRNA dysregulation in psychiatric disease. Brain Res 2010; 1338:89-99.
18. Mouillet-Richard S, Baudry A, Launay JM, Kellermann O. MicroRNAs and depression. Neurobiol Dis 2012; 46:272-278.
19. Rukov JL, Shomron N. MicroRNA pharmacogenomics: posttranscriptional regulation of drug response. Trends Mol Med 2011; 17:412-423.
20. Rukov JL, Vinther J, Shomron N. Pharmacogenomics genes show varying perceptibility to microRNA regulation. Pharmacogenet Genomics 2011; 21:251-262.
21. Valadi H, Ekstrom K, Bossios A, et al. Exosome-mediated transfer of mRNAs and microRNAs is a novel mechanism of genetic exchange between cells. Nat Cell Biol 2007; 9:654-659.
22. Vickers KC, Palmisano BT, Shoucri BM, et al. MicroRNAs are transported in plasma and delivered to recipient cells by high-density lipoproteins. Nat Cell Biol 2011; 13:423-433.
23. Pappas TC, Bader AG, Andruss BF, et al. Applying small RNA molecules to the directed treatment of human diseases: realizing the potential. Expert Opin Ther Targets 2008; 12:115-127.
24. Perkins DO, Jeffries CD, Jarskog LF, et al. MicroRNA expression in the prefrontal cortex of individuals with schizophrenia and schizoaffective disorder. Genome Biol 2007; 8:R27.
25. Smalheiser NR, Lugli G, Rizavi HS, et al. MicroRNA expression is downregulated and reorganized in prefrontal cortex of depressed suicide subjects. PLoS One 2012; 7:e33201.
26. Maussion G, Yang J, Yerko V, et al. Regulation of a truncated form of tropomyosin-related kinase B (TrkB) by Hsa-miR-185- in frontal cortex of suicide completers. PLoS One 2012; 7:e39301.
27. Smalheiser NR, Lugli G, Zhang H, et al. Expression of microRNAs and other small RNAs in prefrontal cortex in schizophrenia, bipolar disorder and depressed subjects. PLoS One 2014; 9:e86469.
28. Lopez JP, Fiori LM, Gross JA, et al. Regulatory role of miRNAs in polyamine gene expression in the prefrontal cortex of depressed suicide completers. Int J Neuropsychopharmacol 2014; 17:23-32.
29. Lopez JP, Lim R, Cruceanu C, et al. miR-1202 is a primate-specific and brainenriched microRNA involved in major depression and antidepressant treatment. Nat Med 2014; 20:764-768.
30. Maheu M, Lopez JP, Crapper L, et al. MicroRNA regulation of central glial cell line-derived neurotrophic factor (GDNF) signalling in depression. Transl Psychiatry 2015; 5:e511.
31. Aschrafi A, Verheijen JM, Gordebeke PM, et al. MicroRNA-326 acts as a molecular switch in the regulation of midbrain urocortin 1 expression. J Psychiatry Neurosci 2016; 41:342-353.
32. Azevedo JA, Carter BS, Meng F, et al. The microRNA network is altered in anterior cingulate cortex of patients with unipolar and bipolar depression. J Psychiatr Res 2016; 82:58-67.
33. Torres-Berrio A, Lopez JP, Bagot RC, et al. DCC confers susceptibility to depression-like behaviors in humans and mice and is regulated by miR-218. Biol Psychiatry 2017; 81:306-315..
34. Roy B, Dunbar M, Shelton RC, Dwivedi Y. Identification of microRNA-124-3p as a putative epigenetic signature of major depressive disorder. Neuropsychopharmacology 2017; 42:864-875.
35. Lopez JP, Fiori LM, Cruceanu C, et al. MicroRNAs 146a/b-5 and 425-3p and 24-3p are markers of antidepressant response and regulate MAPK/Wntsystem genes. Nat Commun 2017; 8:15497.
36. Belzeaux R, Bergon A, Jeanjean V, et al. Responder and nonresponder patients exhibit different peripheral transcriptional signatures during major depressive episode. Transl Psychiatry 2012; 2:e185.
37. Fan HM, Sun XY, Guo W, et al. Differential expression of microRNA in peripheral blood mononuclear cells as specific biomarker for major depressive disorder patients. J Psychiatr Res 2014; 59:45-52.
38. Weigelt K, Bergink V, Burgerhout KM, et al. Down-regulation of inflammationprotective microRNAs 146a and 212 in monocytes of patients with postpartum psychosis. Brain Behav Immun 2013; 29:147-155.
39. Sun N, Lei L, Wang Y, et al. Preliminary comparison of plasma notchassociated microRNA-34b and -34c levels in drug naive, first episode depressed patients and healthy controls. J Affect Disord 2016; 194: 109-114.
40. Song MF, Dong JZ, Wang YW, et al. CSF miR-16 is decreased in major depression patients and its neutralization in rats induces depression-like behaviors via a serotonin transmitter system. J Affect Disord 2015; 178: 25-31.
41. Camkurt MA, Acar S, Coskun S, et al. Comparison of plasma microRNA levels in drug naive, first episode depressed patients and healthy controls. J Psychiatr Res 2015; 69:67-71.
42. Wan Y, Liu Y, Wang X, et al. Identification of differential microRNAs in cerebrospinal fluid and serum of patients with major depressive disorder. PLoS One 2015; 10:e0121975.
43. Su M, Hong J, Zhao Y, et al. MeCP2 controls hippocampal brain-derived neurotrophic factor expression via homeostatic interactions with micro- RNA132 in rats with depression. Mol Med Rep 2015; 12:5399-5406.
44. Liu Y, Yang X, Zhao L, et al. Increased miR-132 level is associated with visual memory dysfunction in patients with depression. Neuropsychiatr Dis Treat 2016; 12:2905-2911.
45. Maffioletti E, Cattaneo A, Rosso G, et al. Peripheral whole blood microRNA alterations in major depression and bipolar disorder. J Affect Disord 2016; 200:250-258.
46. Gururajan A, Naughton ME, Scott KA, et al. MicroRNAs as biomarkers for major depression: a role for let-7b and let-7c. Transl Psychiatry 2016; 6:e862.
47. Bocchio-Chiavetto L, Maffioletti E, Bettinsoli P, et al. Blood microRNA changes in depressed patients during antidepressant treatment. Eur Neuropsychopharmacol 2013; 23:602-611.
48. Fiori LM, Lopez JP, Richard-Devantoy S, et al. Investigation of miR-1202, miR- 135a, and miR-16 in major depressive disorder and antidepressant response. Int J Neuropsychopharmacol 2017; 20:619-623.
49. Issler O, Haramati S, Paul ED, et al. MicroRNA 135 is essential for chronic stress resiliency, antidepressant efficacy, and intact serotonergic activity. Neuron 2014; 83:344-360.
50. He S, Liu X, Jiang K, et al. Alterations of microRNA-124 expression in peripheral blood mononuclear cells in pre and posttreatment patients with major depressive disorder. J Psychiatr Res 2016; 78:65-71.
51. Enatescu VR, Papava I, Enatescu I, et al. Circulating plasma microRNAs in patients with major depressive disorder treated with antidepressants: a pilot study. Psychiatry Investig 2016; 13:549-557.
52. Baudry A, Mouillet-Richard S, Schneider B, et al. miR-16 targets the serotonin transporter: a new facet for adaptive responses to antidepressants. Science 2010; 329:1537-1541.
53. Launay JM, Mouillet-Richard S, Baudry A, et al. Raphe-mediated signals control the hippocampal response to SRI antidepressants via miR-16. Transl Psychiatry 2011; 1:e56.
54. Dadkhah T, Rahimi-Aliabadi S, Jamshidi J, et al. A genetic variant in miRNA binding site of glutamate receptor 4, metabotropic (GRM4) is associated with increased risk of major depressive disorder. J Affect Disord 2017; 208:218-222.
55. Lopez JP, Pereira F, Richard-Devantoy S, et al. Co-variation of peripheral levels of miR-1202 and brain activity and connectivity during antidepressant treatment. Neuropsychopharmacology 2017; 42:2043-2051.
56. Miller AH, Maletic V, Raison CL. Inflammation and its discontents: the role of cytokines in the pathophysiology of major depression. Biol Psychiatry 2009; 65:732-741.
57. Swen JJ, Huizinga TW, Gelderblom H, et al. Translating pharmacogenomics: challenges on the road to the clinic. PLoS Med 2007; 4:e209.
58. de Leon J. Pharmacogenomics: the promise of personalized medicine for CNS disorders. Neuropsychopharmacology 2009; 34:159-172.
59. Fisar Z, Raboch J. Depression, antidepressants, and peripheral blood components. Neuro Endocrinol Lett 2008; 29:17-28.
60. Domenici E, Wille DR, Tozzi F, et al. Plasma protein biomarkers for depression and schizophrenia by multi analyte profiling of case-control collections. PLoS One 2010; 5:e9166.
61. Sullivan PF, Fan C, Perou CM. Evaluating the comparability of gene expression in blood and brain. Am J Med Genet B Neuropsychiatr Genet 2006; 141B:261-268.
62. Tsuang MT, Nossova N, Yager T, et al. Assessing the validity of blood-based gene expression profiles for the classification of schizophrenia and bipolar disorder: a preliminary report. Am J Med Genet B Neuropsychiatr Genet 2005; 133B:1-5.
63. Glatt SJ, Everall IP, Kremen WS, et al. Comparative gene expression analysis of blood and brain provides concurrent validation of SELENBP1 up-regulation in schizophrenia. Proc Natl Acad Sci U S A 2005; 102:15533-15538.
64. Miller AH, Raison CL. The role of inflammation in depression: from evolutionary imperative to modern treatment target. Nat Rev Immunol 2016; 16:22-34.
65. Wittenborn AK, Rahmandad H, Rick J, Hosseinichimeh N. Depression as a systemic syndrome: mapping the feedback loops of major depressive disorder. Psychol Med 2016; 46:551-562.
66. Alvarez-Erviti L, Seow Y, Yin H, et al. Delivery of siRNA to the mouse brain by systemic injection of targeted exosomes. Nat Biotechnol 2011; 29:341-345.
67. Lakhal S, Wood MJ. Exosome nanotechnology: an emerging paradigm shift in drug delivery: exploitation of exosome nanovesicles for systemic in vivo delivery of RNAi heralds new horizons for drug delivery across biological barriers. BioEssays 2011; 33:737-741.